XORTX Therapeutics

XRTX · TSX

$0.9201−$0.0487 (−5.03%)TodayMarket closed · Oct 23, 6:56 PM ET

Prev close $0.9688

About XRTX

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Employees: 3
Headquarters: Calgary, Alberta
Listed: Sep 30, 2015
Sector: Health Care
Industry: Pharmaceuticals
Website: xortx.com

Leadership

XORTX Therapeutics executives
Name	Title	Since	Age
Anthony Giovinazzo	—	—	67
Allen Davidoff	—	2018	64
James Fairbairn	—	—	65
Stacy Evans	—	—	50
Stephen Haworth	—	—	74
William Farley	—	—	70
Abigail Jenkins	—	—	48
Raymond Pratt	—	—	74
Patrick Treanor	—	—	56
Paul Van Damme	—	—	74

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.